Le Lézard
Classified in: Health
Subject: PER

Analgesic Solutions Announces New Executive Management Team


WAYLAND, Mass., Sept. 21, 2018 /PRNewswire/ -- Analgesic Solutions LLC, a company that focuses on increasing assay sensitivity in the conduct of clinical trials through consulting, innovative tools, data science, technology and training, announced today changes within its leadership structure. Effective immediately, Robert Newman is promoted to Chief Executive Officer from Chief Operating Officer, Nathaniel P. Katz, MD, MS will move from Chief Executive Officer to Founder & Chief Scientific Officer, Andrea Licari is promoted to Chief Operating Officer from Vice President, Operations, and Arturo Morales, Ph.D. will assume the title Chief Technology & Data Officer. 

(PRNewsfoto/Analgesic Solutions)

"Our company has made remarkable progress under this leadership team, and we collectively remain committed to advancing the technology, tools and ideas that enable our customers to improve clinical trial success rates. This is the concept on which I founded the company and will continue to steer as its scientific leader," said Dr. Katz. "I believe my deep clinical experience, and the business and strategic acumen that Bob and this management team brings, is the right combination to deliver continued company growth, both within and outside the pain space, and expansion into more data-driven application areas."

Robert Newman joined the company in March 2016 and has worked closely with Dr. Katz to formulate the strategy that has enabled Analgesic Solutions to accelerate year-over-year growth in revenues and reach. Prior to joining Analgesic Solutions, he spent over 25 years in various sales and management positions at several biopharmaceutical companies, most recently as Chief Operating Officer at TissueGene Inc., a Rockville, MD based cell and gene therapy biotechnology company.

Dr. Nathaniel Katz is considered one of the leading experts of treatment and clinical study design in pain clinical trials. He is a neurologist and pain management specialist with a distinguished career at Harvard Medical School, Brigham & Women's Hospital and Dana Farber Cancer Institute. Dr. Katz founded Analgesic Solutions in 2006 with the mission of modernizing the design and conduct of pain clinical trials to advance the scientific quality of clinical research and empower effective treatments for subjects. Dr. Katz holds the position of Adjunct Assistant Professor of Anesthesia at Tufts School of Medicine. Dr. Katz was an Associate Editor at the Clinical Journal of Pain, and Associate Editor (Pain) for the Encyclopedia of Neurological Sciences.

Andrea Licari joined the company in April 2017 as Vice President of Operations. She has spent her career leading the operations of healthcare technology companies focused on improving the health of patients by optimizing patient education, treatment and outcomes. Andrea's passion and expertise is in developing strategies to achieve team and organizational effectiveness.  Prior to Analgesic Solutions, Andrea was the Chief Operating Officer at Modus Health and Inflexxion, Inc.

Arturo Morales, Ph.D. joined the company in June 2016 as Chief Technology Officer. Upon completing his doctoral work with Dr. Paul Schimmel at Massachusetts Institute of Technology (MIT), Dr. Morales started his industry career with Genome Therapeutics as a Senior Computational Biologist. He subsequently led a variety of biology, IT and data science teams at various companies, including the Novartis Institutes for Biomedical Research, where he was Global Lead for Biology Platform Informatics.

ABOUT ANALGESIC SOLUTIONS

Analgesic Solutions, LLC., founded in 2006, is a privately held company that reduces the risks in clinical trials through consulting, innovative tools, data science, technology and training. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the premier choice for mitigating risk associated with measurement error in clinical trials.

http://analgesicsolutions.com 

 

SOURCE Analgesic Solutions


These press releases may also interest you

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...

at 03:03
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark. With the solution, they aim to elevate the educational...

at 03:00
Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).  ...

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...



News published on and distributed by: